AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

'We really do earnestly believe AI could kill all humans!' ...

Ginkgo Bioworks has pivoted to autonomous lab infrastructure in an attempt to capitalize on emerging AI tailwinds. Read more ...

Alphabet high CapEx spending is prudent given the all-or-nothing nature of the AI race, with data centers retaining value.

Microsoft Threat Intelligence observed a human-operated intrusion campaign that abuses Microsoft Teams external collaboration to impersonate IT support, gain remote access, and deploy a Node.js-based ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...